Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Quebec, Canada Clinical Trials

A listing of Quebec, Canada clinical trials actively recruiting patients volunteers.

RESULTS

Found (4) clinical trials

A Phase 1 Study of [225Ac]-FPI-1434 Injection

This is a first-in-human Phase 1, non-randomized, multi-center, open-label clinical trial designed to investigate the safety, tolerability, pharmacokinetics of [111In]-FPI-1547 Injection and [225Ac]-FPI-1434 Injection and to establish the maximum tolerated dose of a single [225Ac]-FPI-1434 Injection in patients with solid tumours with demonstrated tumour uptake of [111In]-FPI-1547.

Phase

0.17 miles

Learn More »

A Study to Describe the Safety Profile and Compare the Immune Response of 4 Differents Formulations of an Investigational Tdap Vaccine When Compared to Licensed Tdap Vaccine in Young Adults in Canada

Study duration per participant is approximately 12 or 14 months for a total of up to 10 visits (depending upon group assignment) including a 12-month follow-up period after last vaccine administration.

Phase

1.75 miles

Learn More »

Study Assessing the Safety Tolerability Pharmacokinetics Food Effect and Drug-Drug Interactions of PTI-801 in Healthy Volunteers and Safety Tolerability and Pharmacokinetics of PTI-801 in Subjects With Cystic Fibrosis

PART 1 The SAD treatment group is comprised of three cohorts where HV will be randomized to either PTI-801 or placebo. Following the conclusion of at least three SAD cohorts, a set of HV will participate in an assigned MAD treatment group. The MAD treatment group is comprised of three ...

Phase

4.9 miles

Learn More »

A Bronchoprovocation Study to Assess the Safety Tolerability Pharmacokinetics and Pharmacodynamics of CSJ117 in Adult Subjects With Mild Atopic Asthma

This is a non-confirmatory, randomized, subject and investigator blinded, placebo-controlled, parallel-design, multi-center bronchoprovocation study. Approximately 55 subjects with mild stable atopic asthma who exhibit an EAR and LAR to a common inhaled allergen will receive multiple once daily doses of inhaled CSJ117 or placebo over 12 weeks. Two sequential dose ...

Phase

4.9 miles

Learn More »